Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 1.00 |
| ▸ | HRH1 | P35367 | 16/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.71 |
| ▸ | HTR1D | P28221 | 1/20 | 0.71 |
| ▸ | HTR1E | P28566 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maritupirdine SCHEMBL30149466 | 1.00 | HTR6 (1.00) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| Maritupirdine SCHEMBL29467339 | 0.99 | HTR6 (0.98) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL8027786 | 0.93 | HRH1 (0.87) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL8034680 | 0.93 | HRH1 (0.87) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL3715259 | 0.93 | HTR6 (1.00) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL3239519 | 0.92 | HRH1 (0.84) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL8035213 | 0.89 | HTR6 (0.89) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL15868711 | 0.89 | HTR6 (0.89) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL633118 | 0.89 | HRH1 (0.80) | HTR6HRH1ADRA2AADRA1AHTR2A | |
| SCHEMBL14963874 | 0.88 | HTR6 (0.87) | HTR6HRH1ADRA2AADRA1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | SAVCHUK, NIKOLAY FILIPPOVICH | 2024-07-18 | — | — | US | disclosed |
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | SAVCHUK, NIKOLAY FILIPPOVICH | 2024-07-18 | — | — | US | disclosed |
| EP-4137208-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, AND METHOD FOR PRODUCING SAME AND USING SAME | Savchuk, Nikolay Filippovich (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2019-08-01 | — | — | US | disclosed |
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2184064-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2145887-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009082268-A2 | LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | ALLA CHEM, LLC (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008123800-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES | ALLA CHEM, LLC (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123796-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008060190-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | ADORA3, HTR3C, TRPV3 | HTR6 6/4885HRH1 139/4885ADRA2A 154/4885 |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | HTR6, HTR3C, HTR3B | HTR6 1/4885HRH1 145/4885ADRA2A 200/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | HTR6 10/4885HRH1 31/4885ADRA2A 200/4885 |
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR2A, HTR1A, HTR2B | HTR6 14/4885HRH1 285/4885ADRA2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.